Enixum, 4000 anti-ha me/0.4ml 0.4 ml 10 pcs

• Prevention of venous thrombosis and embolism in surgical interventions, especially in orthopedic and general surgical procedures;
• prevention of venous thrombosis and embolism in patients on bed rest due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure.Prevention of venous thrombosis and embolism in bedridden patients due to acute medical conditions, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), acute respiratory failure; acute infectious diseases; acute stages of rheumatic diseases combined with a risk factor for venous thrombosis (see “Special Instructions. “
• treatment of deep vein thrombosis with or without pulmonary embolism;
• prevention of thrombosis in extracorporeal circulation during hemodialysis (usually with a session duration of 4 hours or less);
• treatment of unstable angina and myocardial infarction without Q-wave in combination with acetylsalicylic acid;
• treatment of acute ST-segment elevation myocardial infarction in patients undergoing drug treatment or subsequent percutaneous coronary intervention.

Active ingredient

Enoxaparin sodium

Composition

1 syringe (0.4 ml) contains as active ingredient enoxaparin sodium 4000 anti-Ha IU (40 mg);

How to take, the dosage

Enixum® is administered subcutaneously (deeply), in special cases into the arterial circuit during hemodialysis and intravenously.
The drug must not be administered intramuscularly!

Interaction

Enixum® must not be mixed with other drugs in the same syringe.

Enixaparin sodium should not be alternated with other low molecular weight heparins, since they differ in manufacturing method, molecular weight, specific anti-Xa activity, units and dosage. As a consequence, preparations of low molecular weight heparins are characterized by different pharmacokinetics and biological activity (anti-IIa activity, interaction with platelets).

Enixum® is not recommended for use in combination with:

• salicylates and acetylsalicylic acid in doses that have analgesic, antipyretic and anti-inflammatory effects: increased risk of bleeding (due to inhibition of platelet function by salicylates and damage to the mucosa of the stomach and duodenum);
• NSAIDs (nonsteroidal anti-inflammatory drugs) for systemic use: increased risk of bleeding (inhibition of platelet function by NSAIDs and damage to the mucous membrane of the stomach and duodenum). If concomitant use cannot be avoided, close clinical monitoring of the patient is necessary;
• dextran (parenteral administration): increased risk of bleeding (inhibition of platelet function by dextran 40).

Hyperkalemia may occur with potassium salts, potassium-saving diuretics, angiotensin-converting enzyme inhibitors, angiotensin-II antagonists, cyclosporines, tacrolimus and trimethoprim.

The anticoagulant effect of enoxaparin sodium is enhanced with concomitant use with oral anticoagulants.

Concomitant use with platelet aggregation inhibitors (acetylsalicylic acid in antiplatelet doses in cardiac and neurological diseases, clopidogrel, abciximab, ticlopidine, eptifibatide, tirofiban, beraprost, iloprost) increases the risk of bleeding.

Special Instructions

When prescribing the drug for prophylactic purposes, no tendency to increased bleeding has been revealed. When prescribing the drug for therapeutic purposes, there is a risk of bleeding in elderly patients (especially over 80 years). Close monitoring of the patient’s condition is recommended.

Contraindications

• Ensensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins;
• circumstances and diseases with a high risk of bleeding: threatened abortion, cerebral vascular aneurysm, or dissecting aortic aneurysm (except for surgery);
• hemorrhagic stroke;
• uncontrollable bleeding;
enoxaparin- and heparin-induced thrombocytopenia;
• not recommended for use in pregnant women with artificial heart valves;
• age below 18 years of age (efficacy and safety not established).

With caution

• disorders of hemostasis (including hemophilia, thrombocytopenia, hypocoagulation, Willebrand disease, etc.), severe vasculitis;
• Gastric or duodenal ulcer or other gastrointestinal erosive and ulcerative lesions;
• Last ischemic stroke;
• diabetic or hemorrhagic retinopathy;
• severe diabetes mellitus;
• recently undergoing or suspected neurological or ophthalmologic surgery;
• spinal or epidural anesthesia (potential risk of hematoma), spinal tap (recent);
• future delivery;
• bacterial endocarditis (acute or subacute);
• pericarditis or pericardial effusion;
• intrauterine contraception (IUDs);
• severe trauma (especially central nervous system (CNS)), open wounds on large surfaces;
• concurrent administration of drugs that affect the hemostatic system.

There are no data about the clinical use of the drug in the following diseases: active tuberculosis, radiation therapy (recent).

Side effects

WHO classification of adverse drug reactions by frequency of occurrence:
Very frequent – 1/10 appointments (≥10%)